Camille L. Bedrosian
2018
In 2018, Camille L. Bedrosian earned a total compensation of $4.8M as Chief Medical Officer and Executive Vice President at Ultragenyx Pharmaceutical.
Compensation breakdown
| Bonus | $210,000 |
|---|---|
| Non-Equity Incentive Plan | $189,274 |
| Option Awards | $2,906,983 |
| Salary | $442,308 |
| Stock Awards | $990,000 |
| Other | $107,727 |
| Total | $4,846,292 |
Bedrosian received $2.9M in option awards, accounting for 60% of the total pay in 2018.
Bedrosian also received $210K in bonus, $189.3K in non-equity incentive plan, $442.3K in salary, $990K in stock awards and $107.7K in other compensation.
Rankings
In 2018, Camille L. Bedrosian's compensation ranked 2,103rd out of 14,244 executives tracked by ExecPay. In other words, Bedrosian earned more than 85.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,103 out of 14,244 | 85th |
Division Manufacturing | 762 out of 5,759 | 87th |
Major group Chemicals And Allied Products | 254 out of 2,122 | 88th |
Industry group Drugs | 202 out of 1,811 | 89th |
Industry Pharmaceutical Preparations | 156 out of 1,385 | 89th |
Source: SEC filing on April 22, 2019.
Bedrosian's colleagues
We found six more compensation records of executives who worked with Camille L. Bedrosian at Ultragenyx Pharmaceutical in 2018.
2018
Wladimir Hogenhuis
Ultragenyx Pharmaceutical
Chief Operating Officer
2018
Emil Kakkis
Ultragenyx Pharmaceutical
Chief Executive Officer
2018
Shalini Sharp
Ultragenyx Pharmaceutical
Chief Financial Officer
2018
Karah Parschauer
Ultragenyx Pharmaceutical
General Counsel
2018
Thomas Kassberg
Ultragenyx Pharmaceutical
Chief Business Officer and Executive Vice President
2018
John Pinion
Ultragenyx Pharmaceutical